<p>纽约，2025 年 12 月 4 日（GLOBE NEWSWIRE）——Protara Therapeutics, Inc.（纳斯达克：TARA）（“Protara”）是一家开发用于治疗癌症和罕见疾病的变革性疗法的临床阶段公司，今天宣布其承销的公开发行定价为 13,043,479 股普通股，公众发行价格为每股 5.75 美元。此外，Protara 已向承销商授予 30 天的选择权，以以公众发行价格购买最多 1,956,521 股普通股，扣除承销折扣和佣金。此次发行的所有股份均由 Protara 出售。预计此次发行的总收益约为 7500 万美元，未扣除承销折扣和佣金及 Protara 应支付的发行费用，并且不包括承销商行使购买额外股份的选择权。此次发行预计将于 2025 年 12 月 8 日完成，前提是满足惯常的交割条件。Protara 打算将此次发行所获得的净收益用于资助 TARA-002 的临床开发，以及其他临床项目的开发。Protara 还可能将此次发行的净收益用于营运资金和其他一般企业用途。</p>
<p>摩根大通、TD Cowen 和 Piper Sandler 担任联合账簿管理人。LifeSci Capital 担任此次发行的主承销商。H.C. Wainwright &amp; Co.担任此次发行的管理人。</p>
<p>普通股将根据美国证券交易委员会（“SEC”）于 2023 年 11 月 14 日宣布生效的有效货架注册声明（表格 S-3，文件编号 333-275290）发行。此次发行仅通过招股说明书补充及随附的招股说明书进行。与此次发行相关的最终招股说明书补充将在 SEC 备案，并将在 SEC 的网站 www.sec.gov 上提供。最终招股说明书补充及随附的招股说明书在可用时可从摩根大通证券有限责任公司（J.P. Morgan Securities LLC）办公室获取，地址为纽约公园大道 270 号，邮政信箱，纽约，邮政编码 10017，或通过电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；TD Securities（USA）有限责任公司，地址为纽约长岛大道 1155 号，邮政编码 11717，或通过电子邮件联系 TDManualrequest@broadridge.com；或 Piper Sandler &amp; Co.，地址为明尼阿波利斯北 5 街 350 号，1000 套房，邮政编码 55401，注意：招股说明书部门，电话（800）747-3924，或通过电子邮件联系 prospectus@psc.com。</p>
<p>本新闻稿不构成出售任何这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在该州或司法管辖区内的要约、邀请或销售在注册或符合适用证券法之前是非法的。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于非历史事实事项的声明属于 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”。Protara 在某些情况下可能会使用 “预测”、“相信”、“潜在”、“提议”、“继续”、“设计”、“估计”、“预期”、“期望”、“计划”、“打算”、“可能”、“可以”、“会”、“应该” 或其他引用未来事件、条件或情况的不确定性以识别这些前瞻性声明的词语或表达。这些前瞻性声明包括但不限于关于公开发行的时间、规模和完成情况以及相关收益的预期使用的声明，并不保证未来的表现或结果，并涉及重大风险和不确定性。实际结果、发展和事件可能与这些前瞻性声明所表达或暗示的内容有重大不同。导致前瞻性声明不确定性的因素包括：Protara 完成此次发行的能力是否符合提议的条款，或根本无法完成，以及 Protara 对发行收益使用的预期。与前瞻性声明相关的其他重要因素，包括额外的风险和不确定性，已在 Protara 向 SEC 提交的文件和报告中的 “风险因素” 标题下及其他地方进行了更全面的描述。本新闻稿中包含的所有前瞻性声明仅在作出之日有效，并基于管理层在该日期的假设和估计。Protara 没有义务更新任何前瞻性声明，无论是由于收到新信息、未来事件的发生还是其他原因，除非法律要求。</p>
<p><strong>公司联系方式：</strong></p>
<p>贾斯廷·奥马利（Justine O'Malley）</p>
<p>Protara Therapeutics</p>
<p>Justine.OMalley@protaratx.com</p>
<p>646-817-2836</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png"/></p>

TARA

<p>Protara Therapeutics 宣布以每股 5.75 美元公开发行 13,043,479 股，融资总额为 7500 万美元。此次发行包括承销商在 30 天内购买额外 1,956,521 股的选择权。募集资金将用于 TARA-002 及其他项目的临床开发，摩根大通、TD Cowen 和 Piper Sandler 担任联合管理人。此次发行将于 2025 年 12 月 8 日结束</p>

<p>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2025, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>纽约，2025 年 12 月 4 日（GLOBE NEWSWIRE）——Protara Therapeutics, Inc.（纳斯达克：TARA）（“Protara”）是一家开发用于治疗癌症和罕见疾病的变革性疗法的临床阶段公司，今天宣布其承销的公开发行定价为 13,043,479 股普通股，公众发行价格为每股 5.75 美元。此外，Protara 已向承销商授予 30 天的选择权，以以公众发行价格购买最多 1,956,521 股普通股，扣除承销折扣和佣金。此次发行的所有股份均由 Protara 出售。预计此次发行的总收益约为 7500 万美元，未扣除承销折扣和佣金及 Protara 应支付的发行费用，并且不包括承销商行使购买额外股份的选择权。此次发行预计将于 2025 年 12 月 8 日完成，前提是满足惯常的交割条件。Protara 打算将此次发行所获得的净收益用于资助 TARA-002 的临床开发，以及其他临床项目的开发。Protara 还可能将此次发行的净收益用于营运资金和其他一般企业用途。</p>
</div><p>J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers. LifeSci Capital is acting as a lead manager of the offering. H.C. Wainwright &amp; Co. is acting as a manager of the offering.</p>
<div class="lb-trans"><p>摩根大通、TD Cowen 和 Piper Sandler 担任联合账簿管理人。LifeSci Capital 担任此次发行的主承销商。H.C. Wainwright &amp; Co.担任此次发行的管理人。</p>
</div><p>The shares of common stock will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275290) that was declared effective on November 14, 2023 by the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website, at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com; or Piper Sandler &amp; Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.</p>
<div class="lb-trans"><p>普通股将根据美国证券交易委员会（“SEC”）于 2023 年 11 月 14 日宣布生效的有效货架注册声明（表格 S-3，文件编号 333-275290）发行。此次发行仅通过招股说明书补充及随附的招股说明书进行。与此次发行相关的最终招股说明书补充将在 SEC 备案，并将在 SEC 的网站 www.sec.gov 上提供。最终招股说明书补充及随附的招股说明书在可用时可从摩根大通证券有限责任公司（J.P. Morgan Securities LLC）办公室获取，地址为纽约公园大道 270 号，邮政信箱，纽约，邮政编码 10017，或通过电子邮件联系 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；TD Securities（USA）有限责任公司，地址为纽约长岛大道 1155 号，邮政编码 11717，或通过电子邮件联系 TDManualrequest@broadridge.com；或 Piper Sandler &amp; Co.，地址为明尼阿波利斯北 5 街 350 号，1000 套房，邮政编码 55401，注意：招股说明书部门，电话（800）747-3924，或通过电子邮件联系 prospectus@psc.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售任何这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在该州或司法管辖区内的要约、邀请或销售在注册或符合适用证券法之前是非法的。</p>
</div><p><strong>Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding the timing, size and completion of the public offering as well as the expected use of proceeds related thereto are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: Protara’s ability to complete the offering on the proposed terms, or at all, and Protara’s expectations related to the use of proceeds from the offering. Additional important factors to be considered in connection with forward-looking statements, including additional risks and uncertainties, are described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿中关于非历史事实事项的声明属于 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”。Protara 在某些情况下可能会使用 “预测”、“相信”、“潜在”、“提议”、“继续”、“设计”、“估计”、“预期”、“期望”、“计划”、“打算”、“可能”、“可以”、“会”、“应该” 或其他引用未来事件、条件或情况的不确定性以识别这些前瞻性声明的词语或表达。这些前瞻性声明包括但不限于关于公开发行的时间、规模和完成情况以及相关收益的预期使用的声明，并不保证未来的表现或结果，并涉及重大风险和不确定性。实际结果、发展和事件可能与这些前瞻性声明所表达或暗示的内容有重大不同。导致前瞻性声明不确定性的因素包括：Protara 完成此次发行的能力是否符合提议的条款，或根本无法完成，以及 Protara 对发行收益使用的预期。与前瞻性声明相关的其他重要因素，包括额外的风险和不确定性，已在 Protara 向 SEC 提交的文件和报告中的 “风险因素” 标题下及其他地方进行了更全面的描述。本新闻稿中包含的所有前瞻性声明仅在作出之日有效，并基于管理层在该日期的假设和估计。Protara 没有义务更新任何前瞻性声明，无论是由于收到新信息、未来事件的发生还是其他原因，除非法律要求。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系方式：</strong></p>
</div><p>Justine O'Malley</p>
<div class="lb-trans"><p>贾斯廷·奥马利（Justine O'Malley）</p>
</div><p>Protara Therapeutics</p>
<div class="lb-trans"><p>Protara Therapeutics</p>
</div><p>Justine.OMalley@protaratx.com</p>
<div class="lb-trans"><p>Justine.OMalley@protaratx.com</p>
</div><p>646-817-2836</p>
<div class="lb-trans"><p>646-817-2836</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NzQ5NCM3MzA3OTg5IzIxODk3Njg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png"/></p>

Protara 宣布 7500 万美元公开发行的定价 | TARA 股票新闻